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1. Introduction
Nanotechnology-enabled drug delivery systems (NDDS) are associated with high expectations
regarding their economic and societal value. NDDS are expected to contribute to important
issues in healthcare such as enabling novel pharmaceutical therapies which only target the site
of the disease and help to reduce costs of healthcare. To date, more than two dozen NDDS
have been developed into marketed products and many more are under development [1].
Market forecasts have estimated that the market for these technologies will grow from US$ 1
billion in 2010 to US$ 136 billion in 2021 [2, 3].
The pronounced expectations surrounding nanotechnology-enabled drug delivery applica‐
tions and its claimed market potential suggest that the path toward market introduction is
clear. This is however not the case, as is often with newly emerging technologies. While for
instance claims have been made about NDDS contributing to a reduction of undesirable side
effects of drugs (compared to conventional delivery systems), to date limited clinical data is
available to actually support such claims. Uncertainties about the application of regulatory
regimes and which methodologies to apply in order to assess novel nanotechnology-enabled
drug carriers have created further challenges for firms to introduce new products on the
market.
Making promises is almost inevitable in order to attract attention and mobilize resources.
However, too broad promises may make sponsors such as large pharmaceutical companies
and venture capitalists reluctant. Uncertainties about the performance of specific future drug
delivery systems, the demand for such technologies and how they will be evaluated by
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regulatory authorities have contributed to impasses, ‘waiting games’ as we have called them
[1, 4] which constrain development and potential market introduction of NDDS.
In such uncertain and ambiguous situations actors need to make sense of what is happening
already and what might happen [5], before taking a specific course of action. There are two
main strategies available to developers of NDDS to handle this challenging situation. Aca‐
demic entrepreneurs and firms interested in developing and introducing NDDS on the market
may view uncertainties regarding performance and value inevitable and/or postpone such
discussions until a later stage and wait for the ‘invisible hands’ of the market to do its proverbial
work. Or, they can anticipate reception of new products and interact with the broader
environment to work towards the market introduction of what they consider to be desirable
products.
Pro-active interactions will have to go beyond the promotion of promises of nanotechnology-
enabled drug delivery systems in anticipation of the opening up of new markets. Market
success of newly introduced NDDS products involves more than attractive sales figures.
Deuten et al. [6] argued for broadening the notion of market success by thinking in terms of
what they call ‘societal embedding’. They characterized societal embedding by three dimen‐
sions (p. 132): (1) Integration: new technologies need to be integrated in industries and markets;
that is, within business practices and repertoires of users, in this case clinicians and patients.
(2) Admissibility: new products need to be acceptable according to rules and standards within
the sector or set by the government. Think for instance of good manufacturing practices, pre-
clinical testing and clinical trials. (3) Acceptance: new products have to be accepted by the
public. That is, societal concerns should not be too strong, there should be sufficient articulation
in order to make well-informed choices by clinicians and patients, and the product should
actually be used.
Pro-active action then requires taking a broader perspective than that of a single actor, saying
an academic researcher or a start-up firm with a patent in the field of NDDS. Societal embed‐
ding involves a variety of issues which create openings for different actors - who have different
interests in, and perspectives on, emerging NDDS - to engage in strategic actions and interac‐
tions. In the drug delivery sector, firms, governmental bodies, health insurers, scientists,
clinicians and patient organizations are all more or less involved in interactions with respect
to one or more dimensions of societal embedding. Thus, important dynamics related to the
market introduction of NDDS exist at the level of the drug delivery sector rather than at the
level of individual academic or business entrepreneurs. Put differently, for the market
introduction of NDDS entrepreneurial individuals and organizations are dependent on
interactions with other players in the sector which is beyond their full control. Pro-active action
then requires understanding of what happens at the level of the domain and feeding back such
insights into individual or collective strategies to further development and market introduc‐
tion of NDDS.
Anticipation on future market introduction and embedding may seem the wiser option
compared to trial-and-error strategies, but is also difficult and precarious. Anticipation on how
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new technologies become embedded is difficult in itself, due to uncertainties regarding how
new products will eventually look like and their impacts. Anticipation of how other involved
actors perceive and cope with parts of the embedding process and what this means for
individual actors’ strategies then introduces further complexities. Yet, taking into account
these perspectives and strategies is exactly what is important in the case of the drug delivery
sector, which consists of an intersection of different value chains with a large number of
mutually dependent actors. Then how to anticipate future market introduction and embedding
of nanotechnology-enabled drug delivery systems? How to support articulation of anticipa‐
tory strategies and decision making of, say academic and business entrepreneurs, taking into
account other actors’ perspectives in the domain of drug delivery systems?
The question of anticipation of future introduction and embedding of NDDS is a common
challenge of emerging technologies. Within the field of technology assessment a number of
approaches have been developed to deal with uncertainties of emerging technologies empha‐
sizing interactive anticipatory approaches such as real-time technology assessment [7],
anticipatory governance [8], interaction research in lab-settings [9] and constructive technol‐
ogy assessment [10]. Such approaches are devised to support stakeholders in their anticipatory
competences and to support strategies and decision making. These approaches differ in terms
of scope, i.e. which dynamics and actors are taken into account, and in their main target
audience, i.e. whose strategy articulation and assessment is actually supported.
In this chapter I will focus on the approach of Constructive Technology Assessment (CTA)
which has a particular emphasis on exploring future developments with stakeholders in a
domain and feeding insights back to researchers and technology developers. This approach is
by now well established and has been applied for different nanotechnologies and their
applications. I will describe the methodology of CTA scenario workshops and demonstrate
the approach by offering the results of a study [11] where this approach was used to map and
support anticipation of opportunities and challenges of nanotechnology-enabled drug
delivery technologies.
In section 2 I will start with offering a general perspective on how different types of actors
perceive and assess emerging technologies. This is important to recognize when interacting
with a variety of involved actors and forms the backdrop against which I position the meth‐
odology and approach of Constructive Technology Assessment and its scenario workshops. I
will describe the CTA methodology and discuss how to organize and prepare for such
interactive workshops. In section 3 I will set the scene for the workshops by briefly describing
the main actors involved in the drug delivery sector and the promises of NDDS. In section 4 I
will report on the preparation of the workshops and discuss in detail the main lines of
discussion in the workshop and participants’ assessments of the situation in which the drug
delivery sector finds itself regarding emerging nanotechnologies. In section 5 I will conclude
by summarizing main findings and reflecting on the merits of the CTA approach for antici‐
pating, and supporting anticipation of, market introduction of nanotechnology-enabled drug
delivery systems.
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2. Constructive technology assessment & scenario workshops
2.1. Perspectives on emerging technologies
There are structural differences in how actors perceive and interact with novel technologies.
In our modern societies there exists an asymmetry between those who develop new science
and technology and those who are impacted by these developments. For one this is related to
a difference in timing between the development and actual introduction of new technologies;
for another it is related to differences in involvement and perspective of a variety of actors
which to some extent is institutionalized in a historically grown division of labour regarding
novel technologies. That is, there exists a separation between individuals and organizations
involved in either the generation or the uptake – ‘selection’ - of technologies. For instance,
technology actors have had ‘a mandate’ to develop new technologies and could confront
society with new technologies when linked with ideals of progress. Even if this mandate is not
taken for granted anymore, it has led to institutions and divisions of labour with respect to the
promotion and selection or regulation - ‘control’ - of new technologies which cannot easily be
undone [12].
For  understanding  actors’  perspectives  and  interactions  regarding  (emerging)  technolo‐
gies  the  actor  typology  developed  by  Garud  and  Ahlstrom  [13]  is  helpful.  Garud  and
Ahlstrom emphasize the structural difference in the ways actors assess technologies. They
relate differences in views and action perspectives to two different positions: insiders and
outsiders with respect to technologies. To emphasize the difference in position and style,
rather than inside/outside boundaries, the terms enactors and comparative selectors have
been proposed [14].
As we formulated in the yearbook Nanotechnology in Society [15], enactors, i.e. those who
promote and aim to realize novel technologies “construct scenarios of progress, and identify
obstacles to be overcome. They thus work and think in ‘enactment cycles’ which emphasize
positive aspects. This includes a tendency to disqualify opposition as irrational or misguided,
or following their own agendas. For nanotechnology, enactors now also anticipate obstacles
similar to the ones which occurred for GMO (Genetically Modified Organisms) in agriculture
and food, cf. Colvin [16].”
Enactors will identify with a novel technology and its applications such as nanotechnology-
enabled drug delivery systems and may believe that the world is waiting for these products,
e.g. because of its attractive performance characteristics and ‘a good product sells itself’.
However, for ‘the world’ the product is just one of many options and it may see alternatives.
This group takes a position of comparing and selecting different technological options, thus
act as ‘comparative selectors’. While enactors may downplay considerations regarding costs
and risks, selectors will often take broader evaluation frames where these considerations are
put upfront [13: 40].
There can be different types of such so called ‘comparative selectors’. This act of ‘comparative
selecting’ can be done on a professional basis, such as health insurance authorities deciding
which novel drugs are worth reimbursing and to be included in insurance packages on the
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basis of cost-benefit analysis, or the Food and Drug Administration deciding whether or not
to grant market access to novel drugs. It can also be done by actors who are less tied to certain
methods such as patients and their individual experience with specific medication. Public
interest groups may act as selectors, for instance organizations which have opposed the
introduction of GMOs or those who have called for more control and regulation of nanotech‐
nologies such as the ETC Group [17].
These different positions may, and sometimes have to, interact with each other. For instance
in the case of drug delivery, firms aiming to introduce novel drugs will at some stage have to
interact with the US Food and Drug Administration and/or the European Medicines Agency
or other regulatory body. Firms acting as enactors of drug delivery systems will have to act
with pharmaceutical companies who (then) may act as selectors, choosing between different
delivery devices to be used for their pharmaceutical agent. They may also meet each other at
conferences or in dedicated discussion platforms which may be set-up to foster mutual
understanding.
Actors pursuing promotion activities and actors pursuing selection activities will interfere
anyway, eventually. The next step then is to identify where and when these activities interfere
and what happens there. That is, what do these different actors learn at these occasions from
each other. How does that shape how they view the novel technology under consideration and
what does this imply for their strategies regarding development or uptake of novel technolo‐
gies. Garud & Ahlstrom (1997) call such occasions ‘bridging events’ and discuss some
examples.
The important point here is that such bridging events can be created on purpose. This can be
done by technology enactors themselves who for instance engage in market research, or by
selectors such as regulatory authorities who invite sponsors of new pharmaceutical therapies
to discuss their future products and how to evaluate them. It can also be done by academic
researchers or more disinterested actors who are working with the perspective of Constructive
Technology Assessment (CTA).
2.2. Constructive technology assessment
The approach of Constructive Technology Assessment (CTA) has been developed since the
1980’s and has become a key methodology within the field of technology assessment. It aims
to broaden design, development and implementation processes rather than only assess
impacts on novel technologies [18]. In CTA, technologies and their impacts are not seen as
given. “For CTA, the dynamics of the process are central, and impacts are viewed as being
built up, and co-produced, during the process of technical change. Many technology studies
have shown that impacts are not just passive effects of a given technology on its environment,
but are actively sought (or avoided) by technology producers, users, and third actors such as
governments, unions, and pressure groups alike” [18, p. 257]. Technologies and their impacts
co-evolve, and actors involved try to shape this process and make assessments of what is
happening or could happen.
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CTA does not aim to introduce assessment – as enactors/selectors are making assessments the
entire time- but rather to modulate ongoing processes of assessment and feedback into actor
decisions and strategies with respect to technology development and introduction. In partic‐
ular it aims to broaden actors perspectives by offering an overview of actors and aspects
involved in development and embedding of emerging technologies [19]. Second, it aims to
enrich actors understanding of the dynamics of such processes, for instance the role of
reimbursement in health care innovations. By broadening and enriching perspectives of actors,
CTA interventions aim to support individuals and organizations in identifying their role and
impacts in the overall innovation processes. This helps actors to evaluate effects of their
strategies and consider what they may need to change in their activities in the present and near
future in order to work towards desirable outcomes (for instance to improve chance of market
success of new NDDS).
While CTA events are an intervention, they are also a tool to understand what is happening
in a particular domain of technology. They provide an entrance point to elicit perceptions of
enactors and comparative selectors in an interactive setting. As we formulated it [15], it is
creating and orchestrating spaces where interactions occur, even if the interactions between
citizens/consumers and technology developers and promoters will always be partial (because
of their difference in perspective). There will be “probing of each other’s realities” (as Garud
and Ahlstrom (1997) called it), with more or less contestation.
The CTA workshop which convenes stakeholders in a particular domain, is a micro cosmos
which reflects parts of the macro cosmos, in this case the drug delivery sector, through
participants’ interactions and their assessments of the force fields in which they find them‐
selves. The workshops provide a space in which actors with different socio-cognitive positions,
which I summarized as enactors and comparative selectors, can interact. Thus, the temporary
space is a bridging event, and is designed as a bridging event.
Within this general framing, CTA workshops are tailored towards stimulating actors’ antici‐
pation of embedding through broadening and enriching actors’ assessments of ongoing
dynamics, and actors’ articulation of possible embedding strategies. Facilitating interactions,
especially mutual ‘probing’, between enactors and selectors is one of the mechanisms. At the
same time, interactions between enactors and selectors offer insights into what is happening
in a domain. Supported by careful preparation – ‘pre-engagement’ [20] – CTA workshops then
provide a ‘window on the world’ to the participants; their world as it is, and might be in the
future. The articulations in this micro cosmos then will offer a view of potential developments
in the domain. On the other hand, the temporary (and protected) space of the workshop will
not fully reflect the force fields in the macro cosmos. Still, the patterns that are found in actors’
articulations and their assessments of force fields affording actions, offer good indications.
One reason is that participants probe into or comment on each other’s positions and consid‐
erations, introducing checks on what happens in the drug delivery sector.
In interactive workshops, probing and commenting can be supported by socio-technical
scenarios. In the case of nanotechnologies, socio-technical scenarios are necessary to address
their doubly fictional character [15]. Many of the expected applications enabled by nanotech‐
nologies (and nanosciences) are still envisioned, part of ‘science fiction’. The eventual impacts
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of such applications are unclear, and attempts to find out about impacts amount to social
science fiction. Socio-technical scenarios capture ongoing dynamics and develop assessments
of future developments. They show the effects of interactions between enactors and selectors
which provides more substance to interactions in workshops as actors can draw upon the
scenarios for inspiration.
The use of scenarios and interactive workshops has further effects. They provide participants
in workshops with competences to support anticipation and strategy articulation. Tools such
as scenarios, which are based on insights in ongoing dynamics and debates during interactive
workshops, provide actors with understanding of the overall situation and clues for how to
take into account ongoing developments and future impacts. So, while actors will likely value
anticipation of embedding as a prudent strategy relevant for their own activities, they now are
also provided with some skills to fill in such strategies.
2.3. Workshop design and preparation
To prepare for a CTA workshop, the actual ‘engagement’ between stakeholders, the organizers
of this event need to prepare themselves, or ‘pre-engage’ with the technologies and domains
under consideration, in this case NDDS in the drug delivery sector. Preparing for the work‐
shops clearly includes an organizational component, such as identifying possible collabora‐
tors, preparing input documents for the workshops themselves, and interactions with
participants and actors potentially interested in participating in the workshop. Preparing also
requires analysis to support anticipation in a situation filled with uncertainties. This helps to
focus the discussion on key issues and be more productive while at the same time the organ‐
izers should remain open for other themes and questions.
The organizers of a CTA event need to have a thorough understanding of the emerging science
& technology. What are the dynamics in its development, to what extent is there still room to
change the course of technology developments and how these technologies can be integrated
in business practices, and how they are perceived by regulatory authorities and further
individuals and organizations in society. A second requirement is that organizers need to have
a sense of various actors’ willingness to anticipate future developments and tune their activities
with other actors in the domain. For instance some companies may not be willing at all to
engage in co-ordination activities with other companies or societal actors. A third requirement
is to identify, select and position potential participants which is related to their role in the
overall technology development and embedding process. For instance large pharmaceutical
companies are important in the overall innovation process and should ideally be included in
such an exercise. For a productive discussion the workshops benefit from an appropriate mix
of participants with an enactor or selector perspective toward the technologies under consid‐
eration [19]. Finally, the organizers should be aware of broader dynamics which may not
always be immediately obvious to actors involved in developing novel technologies. In the
case of the drug delivery sector, one may consider involving health insurers as they may be
not directly involved in developing new options, but will definitely be important when new
pharmaceutical options are introduced on the market.
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The design of a CTA workshop can take different shapes, see also [19, 21], but will often be
geared toward eliciting actors’ perspectives on societal embedding of emerging technologies
and to stimulate broadening and enriching of understanding of dynamics in development and
future introduction of these technologies. To do so the workshop can be structured around
two themes which will be recognizable for participants: (1) identification of challenges,
opportunities and directions for development of emerging technologies in a specific domain;
(2) identification of ways to cope with challenges and opportunities of these technologies.
These are broad themes in order to simulate actors to articulate linkages between emerging
technologies like NDDS and aspects of societal embedding and prevent too early lock-ins into
particular options or strategies. Such open-ended character will often be unavoidable consid‐
ering the emergent character of the application of technologies. It was intentionally open-
ended in order to allow for open discussion
Some reduction of the open-ended character of these two discussion themes will be important
in order to have a productive meeting and attract participants. In CTA workshops this is often
done by means of a preparatory document which will be given to all participants, justifying
and framing the meeting. To link up with interests of potential participants, such a document
can identify key issues and dilemmas which will be recognizable to at least part of the
participants. In addition the document will contain the scenarios about future developments.
These scenarios depart from major challenges in the present situation and explore strategies
to overcome them, including the possible responses of actors involved, for scenario method‐
ology see also [15, 20, 22]. In this way the scenarios help to make anticipations of future
developments concrete and can support actors in their formulation of strategies.
Finally, to stimulate an open discussion and overcome possible concerns regarding confiden‐
tiality, a CTA workshop can be held under the ‘Chatham House rule’. This rule is as follows:
"When a meeting, or part thereof, is held under the Chatham House Rule, participants are free
to use the information received, but neither the identity nor the affiliation of the speaker(s),
nor that of any other participant, may be revealed” [23]. By adopting this workshop rule, the
organizers aim to create an informal atmosphere and stimulate an open discussion.
Before I will discuss the results of the workshop discussions I will briefly introduce the drug
delivery sector and nanotechnology.
3. Setting the scene: Nanotechnology in the drug delivery sector
The drug delivery sector consists of different value chains related to the technology under
consideration. A drug delivery system is a formulation or device “that delivers therapeutic
agent(s) to desired body location(s) and/or provides timely release of therapeutic agent(s). The
system, on its own, is not a therapy, but improves the efficacy and/or safety of the therapeutic
agent(s) that it carries.”1 These delivery devices can not only be used as carriers for drugs but
can also be applied for medical imaging purposes and as carriers for food ingredients. The
1 From www.drugdel.com/glossbot.htm
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drug delivery sector, then, is an intersection of two product value chains involving the ‘primary
manufacturing’ of the active pharmaceutical ingredient (API) and the ‘secondary manufac‐
turing’, i.e. the formulation (including drug delivery systems) and packaging. Both stages of
manufacturing can occur within one (integrated) firm or be outsourced to contractors [24].
Dynamics in the sector then come from both chains and their intersection, but also from the
broader health care environment in which these chains are embedded. For embedding new
drug delivery systems, enactors, e.g. business entrepreneurs, not only need to deal with
business dynamics in the world of pharma, but also with broader developments in health care
such as overall pressures on cost reduction of treatments, debates on reimbursement. In
addition to firms, there are knowledge institutes, clinicians, patients, governmental actors and
health insurers. Figure 1 offers a (simplified) overview of actors in the drug delivery sector.
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Figure 1. Organizations in the drug delivery sector
The development and introduction of nanotechnologies plays against a backdrop of increasing
difficulties of pharmaceutical companies to develop and market new drugs [25, 26]. Nano‐
technology-enabled drug delivery systems promise new solutions. The application of nano‐
technologies which has attracted the most attention is the promise of releasing drugs at a
particular target. While there are other targeting approaches, nanotechnology engineered
delivery systems are considered to be particularly promising. In a conventional delivery
system, the drug is distributed systemically across the body, but this may not always be
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sufficiently (therapeutically) effective or have adverse toxic effects. For targeted drug delivery
there are two general approaches. Drugs can be released near the desired location in the body
or drugs can be designed for active or passive targeting purposes. In both cases the application
of nanotechnologies (devices and molecules) promises to contribute to targeted delivery.
The promise of targeted delivery is not entirely new. The concept of drug targeting is linked
with Paul Ehrlich’s idea of ‘Zauberkugeln’, ‘magic bullets’ introduced over a century ago. The
‘magic bullet’ refers to the idea of homing in on the target and being effective - in this case
affecting only the diseased tissue. Work on what are now considered to be nanotechnology
enabled drug delivery systems has evolved since the 1960s [27-29] – although not exclusively
related to targeting. Systems which are currently labeled as ‘nanovehicles’ have existed for
some time, such as liposomes and polymer micelles (1960s), nanoparticles and dendrimers
(1970s) [30]. The connection with the term ‘nano’ can thus be considered as a relabeling of what
was already occuring.
Pharmaceutical challenges Expected solutions from NDDS
Difficult or unacceptable pharmaceutical format due to
poor solubility or toxicities linked to particular excipients.
Enhancing drug solubility, e.g. by micelles and liposomes
providing hydrophilic and –phobic environments.
Undesirable side-effects caused by extravasation (e.g. by
leakage) of drugs from diseased to surrounding tissues.
Regulated drug release can reduce or prevent tissue
damage by extravasation.
Loss of activity of drugs due to rapid breakdown in the
body.
NDDS protect drugs from premature degradation and
may enable use of lower doses.
Loss of activity due to too rapid clearance of drugs. NDDS can reduce clearance and may enable use of lower
doses.
Undesirable side-effects due to too widespread distribution
in the body affecting healthy tissues.
Particulate character of NDDS lowers distribution and
helps to reduce side-effects.
Suboptimal therapeutic effects due to use of low
concentration of drugs to reduce side-effects.
NDDS can increase drug concentrations by passive and
active targeting (EPR-effect, targeting ligands).
Insufficient drug absorption and intracellular penetration. NDDS can improve absorption through epithelium and
improve intracellular penetration and distribution.
Difficult or unacceptable excipients to stimulate immune
responses in case of vaccines.
NDDS can be engineered to stimulate immune response,
e.g. virosomes and virus-like particles.
*Modified and expanded from Allen and Cullis [31] with items from Couvreur and Vauthier [32].
Table 1. Expectations of nanotechnology enabled drug delivery systems
Considering the history of drug delivery systems, promises of the application of nanotech‐
nologies may not be very effective in mobilizing actors. According to Boyd [27] the claim that
“advances in nanotechnology are stimulating a ‘revolution’ in colloidal drug delivery” should
be reconsidered given evolutionary developments over the last decades. Available funding
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related to rhetorics of nanotechnology in general and for drug delivery in particular, as well
as advances at the level of materials, have created new openings for pursuing targeted drug
delivery.
The application of nanotechnology-engineered drug delivery systems (NDDS) is expected to
be beneficial for the generation of novel pharmaceutical therapies and thereby appealing to
current pressures on pharmaceutical companies to generate novel therapies. The idea of the
magic bullet enabled by nanotechnologies is a powerful image. There are further expectations
of the application of nanotechnologies which link up with issues in the drug delivery sector,
in particular the challenge of sustaining pharmaceutical business: (1) creating new drugs or
extension of patent life of existing drugs by providing new and improved formulations with
respect to therapeutical effectiveness and safety; (2) enabling formulations for API’s which are
difficult to develop pharmaceutically, including promising new biopharmaceutical therapies
such as those based on genes. In table 1 an overview of expectations of the applications of
NDDS is presented.
4. Workshop results
4.1. Preparing the interactive workshop
To prepare for a CTA workshop on NDDS it is important to have a solid understanding of
dynamics related to the development and introduction of these emerging technologies. To do
so I addressed the pre-engagement requirements mentioned in section 2.2 Table 2 summarizes
major findings in the pre-engagement phase. For an in-depth discussion of dynamics in the
drug delivery sector, nanomedicine and pharmaceutical developments more generally, see
also [1, 33-35].
For the organization of the drug delivery workshop I co-operated with two (regional) branch
organizations. One of them was an association of companies, including large pharmaceutical
companies, who develop new pharmaceutical products. The other organization was an
association of companies and organizations involved in biotechnology, including pharma‐
ceutical applications. For the former, nanotechnology was not a central topic as it was not (yet)
an important theme for its members. Its members are relatively little involved in R&D activities
and therefore activities in this area are limited almost by definition as many nanotechnologies
are still in a pre-clinical stage. For the other the situation is somewhat different. Biopharma‐
ceutical companies are likely to be interested in nanotechnologies considering the promises
for (difficult) delivery of macromolecules such as siRNA.
2 Mapping of dynamics linked to nanotechnologies and the drug delivery sector was completed by analyzing relevant
reports, papers, conducting interviews and attending international conferences on nanomedicine. Interviews were
conducted with experts in the field in order to map opportunities, challenges and dynamics. In addition, interviews were
used to find out about existing activities to develop new framing conditions, rules and practices and attempts at co-
ordination with respect to nanotechnologies and drug delivery systems [11].
Anticipating Market Introduction of Nanotechnology-Enabled Drug Delivery Systems
http://dx.doi.org/10.5772/57180
511
I expected that attracting workshop participants would be difficult. Large pharmaceutical
companies might not be interested due to waiting games and the low priority for nanotech‐
nologies. Clinicians might not be interested, due to their limited involvement until now. It
indeed proved difficult to attract participants from large pharmaceutical companies and, for
that matter, biopharmaceutical companies, to attend the workshop on drug delivery - despite
efforts by the co-organizing branche organizations. Nanotechnologies were not a high priority
for potential participants and caution in discussing R&D developments were provided as
important reasons for not attending the workshop. Attracting clinicians also proved to be
difficult, albeit for different reasons. While some clinicians were interested in the phenomenon
of nanotechnologies, but not able to attend due to busy schedules, others were sceptical about
the value of nanotechnologies and not interested in participating in the workshop. These
observations are relevant as they already give indications of possible difficulties in bringing
about co-ordination in the field regarding emerging NDDS.
While eventually no clinicians or participants from large pharmaceutical companies attended,
participants from different parts of the chain were present at the workshop, including some
who had experiences with interactions with pharmaceutical companies and clinicians.
Participants from knowledge institutes, suppliers of delivery systems, and a drug develop‐
ment firm were present. In addition, a firm involved with microsystem technologies and a
governmental organization involved with nanotechnologies were present.
To prepare for the discussion and support participants thinking about current and future
developments, three scenarios were crafted. One scenario explored two different (and
Pre-engagement requirements Findings
Understanding of dynamics in the
domain
Focus on promises of targeting applications, but also on other promises such as
longer circulation time of drugs.
Long history of development and few products on the market yet.
Nanotechnologies not high priority on drug delivery sectors’ agenda.
Actors’ propensity to co-ordinate
development and embedding of
NDDS
Waiting games between actors in the value chain.
Emerging consortia and platforms for drug delivery researchers and other
actors interested in drug delivery (often linked to nanomedicine).
Uptake of notion of ‘translational research’.
Selection and position of actors Big pharma as gatekeepers regarding development of new options.
Important to involve and link academia, industry and clinicians
Assessment of broader dynamics Linkages between drug delivery and imaging sector; between drug delivery
and food sector.
Attention to regulatory and clinical aspects, less on broader issues such as
patient involvement, reliability and liability.
Overall developments: reimbursement pressures; mergers and job cuts at large
pharmaceutical companies; perception of nanotechnology risks
Table 2. Summary of pre-engagement drug delivery workshop
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contested) development paths. A consortium of researchers anticipated that demonstrating
clinical value would convince investors in the added value of targeted drug delivery systems
which would contribute to overcoming the current impasse. To do so the consortium focused
on incremental improvements of carriers with which there was already a lot of experience with
regarding safety and effectiveness. Another set of actors disagreed with this approach and
anticipated that big steps were needed in order to fulfill the promises of nano-enabled drug
delivery. This group of actors formed a more ambitious consortium working on theranostics.
The scenario speculated that the eventual fate of the consortia was not so much determined
by its technological achievements but due to contextual factors. Concerns about possible risks
of nanotechnology enabled drug delivery systems and gaps between diagnostic and thera‐
peutic possibilities co-determined the fate of the two development paths. In the end the
ambitious consortium was disbanded.
The two other scenarios explored initiatives which more directly worked on improving co-
ordination across actors in the drug delivery sector. One of these scenarios described the
formation of  a  broad platform involving material  and pharmaceutical  researchers,  clini‐
cians and people from industry. Discussions and differences of opinion among the platform
participants about how to co-ordinate technology developments and their future introduc‐
tion forces the platform to abandon the initial  broad scope and focus on specific carrier
systems.  While  the  platform  is  successful  in  attracting  a  broad  variety  of  stakeholders,
including interested actors from outside the nanomedicine world,  attempts at  co-ordina‐
tion  across  the  domain  are  met  with  criticisms.  One  of  the  co-ordination  mechanisms
proposed by the platform is a stage-gate model which articulates criteria for the develop‐
ment and clinical introduction of novel targeted medicines. According to critics the stage-
gate  model  is  too  restrictive:  commercially  uncertain,  but  potentially  interesting  and
promising technologies are too quickly shifted aside – effectively constraining opportuni‐
ties for breakthrough technologies.
The third scenario explored attempts at stimulation and co-ordination from the demand-side.
An alliance of patient organizations, knowledge institutes and firms is forged with the general
aim of stimulating demand for cancer medicines with little side-effects. The alliance develops
a broad research programme and actively involves itself in political circles and decision
processes on the restructuration of the health care system and reimbursement policies. The
broad focus on stimulating demand for reduction of side-effects of medicines attracts various
alternative technology solutions. Only with help with the reference to cancer medicines, nano-
enabled targeted drug delivery system remain on the agenda within the research programme
which is eventually funded. First clinical evidence suggests that complexity of cancer requires
different forms of drug delivery systems which may be commercially less attractive because
of limited market volumes. Involved patient organizations are disappointed and press for
applications fitting their specific diseases. The push of the alliance for medicines with less side-
effects then starts to lose its momentum. The emphasis on cancers as the major disease area
now appears to be less effective to mobilize resources.
To inform the participants a preparatory document was distributed one week before the
workshop. This document contained: (1) a program of the meeting; (2) a short introduction
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into and justification of the topic of the meeting; (3) a brief analysis of the current situation of
development and embedding of nanotechnologies for drug delivery; (4) the presentation of
scenarios; and (5) a list of identified dilemmas where strategic choices about development and
societal embedding of nanotechnology-enabled drug delivery systems had to be made. The
document aimed to create common ground for participants, and offer ideas for discussion. In
particular the scenarios and dilemmas were offered as ways to think about future develop‐
ments and strategies. It was emphasized that the scenarios were controlled speculations [22],
i.e. imagined developments but based on what was happening in the drug delivery sector
already. Participants were invited to modify and add to the scenarios during the workshop.
4.2. Discussions during the workshop
The workshop consisted of a half-day of intense discussions which took place in an informal
atmosphere.3 While the workshop discussions covered a variety of themes, there was a strong
focus on the clinical value of nanotechnology-enabled drug delivery technologies. Sectoral
issues of co-ordination between disciplines and across positions in the chain emerged as the
most important challenges to be overcome. They were recognized and were actually high‐
lighted by some participants in the workshops as being a key factor holding back embedding
processes of nano drug delivery technologies. The lack of clinical evidence of (significant)
therapeutical effectiveness was positioned as the reverse salient for furthering developments
in the field. Strategies to stimulate and improve further developments in the field of nano-
enabled drug delivery revolved around the challenge of demonstrating clinical value.
Interactions during the targeted drug delivery workshop are characterized as a series of
exchanges on diagnosing the key challenges in furthering developments in the field of
nanotechnologies and drug delivery, and on the best methods to cope with those challenges.
While there was no explicit consensus on which strategies should be pursued in the future,
the emphasis on problems of co-ordination and lack of clinical evidence effectively constituted
a lock-in in the discussion. To show how participants in the workshops assessed current
dynamics and anticipated future developments relevant for the commercialization of nano-
enabled drug delivery systems I will report on salient items in the discussions.
4.2.1. The unique character of nanotechnology and the pharmaceutical sector
Puzzles about the unique character, if any, of nanotechnology engineered drug delivery
technologies set the stage for a series of exchanges. The discussion was initiated by a participant
wondering about specificities of the application of nanotechnologies and how these contrib‐
uted to reluctance in uptake and development of nanotechnology-enabled drug delivery
technologies. A participant from a drug development company replied by pointing out
uncertainties about the unknown safety profile of nanoparticles. Whether this meant that there
was a lack of testing methodologies and knowledge about distribution and effects of nano‐
3 The quotations in this chapter are anonymized, and used with permission of the participants. The quotations were
translated into English by the author.
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particles in the body – which would suggest the existence of specific nanotechnology related
challenges - or required more efforts during testing was unclear.
This question regarding safety of nano drug delivery technologies prompted a participant,
working for a company supplying drug delivery systems, to frame the question differently by
asking about the status of knowledge and methodologies for assessing ‘conventional’ phar‐
maceutical materials. This participant considered questions regarding safety to be the respon‐
sibility of their customers and not a topic for his firm. However, by asking about evaluation
criteria for their customers’ products, his understanding of broader developments increased.
4 In that respect, this participant did consider broader developments rather than only customer-
supplier exchanges.
Delivery systems supplier: May I ask a simple question? We discussed that we cannot observe where
nanoparticles are travelling to, but this is also unknown for pharmaceutical substances, molecules. Also
in these cases one doesn’t analyze in detail whether particles travel to the liver, or to.
Knowledge institute 2: Well, well
Delivery systems supplier: They do?
Knowledge institute 2: There is pre-clinical pharmacokinetics, tissue distribution; this should all be
done.
Governmental organization: But that is not different for what needs to be done already for pharmaceutical
substances.
Delivery systems supplier: Hence, my question. If this is already being done for small molecules, why
would this be problematic for nanoparticles?
Governmental organization: Because for non-nanoparticles, let’s call them that way, for other chemical
substances, not necessarily pharmaceutical compounds, already a number of patterns are known. [...]
The case of nanoparticles is becoming a totally different story for us.
Even if questions concerning the unique character of nanotechnologies for drug delivery were
unsolved, the link between general conceptualizations of the term nanotechnology and drug
delivery was problematized. Participants from research institutes and a drug development
firm pointed out that the associations of targeted drug delivery with the umbrella term
‘nanotechnology’ also, albeit incorrectly, implied connections with discussions of ‘disadvan‐
tages or risks’ linked to nanotechnologies in the public domain. According to these partici‐
pants, such associations could provide nuisances for nano drug delivery technologies. This
type of reasoning shows that these enactors take broader aspects into account, yet in a way
which resembles other patterns which have been called by Rip [14] as ‘folk theories’: taken for
granted patterns, which have not systematically been checked. In this case, the expectation
that nanotechnologies may suffer from the same public backlash as what happened to GMOs.
4 During my post-workshop interviews this participant expressed that understanding in this area helped the firm to
assess their business plan forecasts as uncertainties in this area might slow down introductions of their customers’
products, and therefore the participants’ sales volume.
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A series of interactions followed in which a participant from a governmental organization
questioned this implicit pattern. This participant pointed out that specificities of the drug
delivery sector would limit possible risks of nanotechnologies. Exposure to nanotechnologies
through pharmaceutical therapies would be well controlled and registration procedures
would check, among other things, toxicity. In addition, access to consumers – patients – would
be regulated through intervention of clinicians. Furthermore, authorities had already consid‐
erable experience with delivery systems such as liposomes, suggesting that registration
procedures should not pose particular difficulties. However, the participant acknowledged,
patients might think differently about risks than experts do.
The point about regulatory expertise was contested by one of the participants who had
experience with regulatory authorities, puzzling over whether existing evaluations were
sufficient – even for liposomal formulations. The participant speculated that more knowledge
about risks of nanotechnologies might lead to re-evaluating existing registration procedures.
This prompted a reflective comment from the participant of the governmental organization,
noting that there were tendencies in society to reduce and solve all uncertainties and problems
linked to nanomaterials. While such an objective might be laudable, the participant warned
that one should not increase risk assessment criteria for nanotechnologies beyond what was
presently accepted.
4.2.2. Challenges in co-ordination across the innovation chain
During the discussion the point was made that the development of linkages between research
on drug delivery materials and specific diseases was difficult. A participant from a knowledge
institute suggested that research programmes should stimulate the improvement of interfaces
within a chain of activities involved in developing these linkages. At the same time, this
participant observed that developing linkages would not be straightforward, for different
reasons.
Knowledge institute 1: There are also groups that only focus on researching their own chemical entities
and do not develop them further. While, clearly, further development of these substances should be
considered. In which area do you want to have an application? Then you also need a partner to do this.
We, as material developers, are all confronted with the problem that we have difficulties in reaching
those people, particularly the industrial actors which are interested in these materials.
According to a participant from another knowledge institute, the difficulty in bringing the field
of nanotechnology enabled targeted drug delivery further was rooted in the lack of clinical
evidence. This would make it difficult for researchers and drug delivery firms to link up with
large pharmaceutical companies. Later, the participant commented that big pharmaceutical
companies were to some extent dependent on these new technologies. So, we see here a waiting
game at work, considering that researchers and firms are to some extent dependent on large
pharmaceutical companies for funding and further exploitation of nanotechnology enabled
delivery systems.
Knowledge institute 2: There is still too little on the market that convinces large companies to put effort
in this area. There is very little data on the clinical benefits. Real, concrete proof. And that is what the
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industry is waiting for [..] but big pharmaceutical companies are not in-active altogether. On the one
hand there is a development which forces them to pay attention to these type of products, eventually.
Because there are increasingly less blockbusters. [..] Big pharmaceutical companies do have interest in
these [nano drug delivery] type of systems. Watch it carefully.
According to participants from research institutes, big pharmaceutical industries were
reluctant. This led the participant from the governmental organization to probe into big
pharma’s considerations. While no participant from big pharma was present, participants
replied by referring to big pharma’s waiting strategy, which was considered to be independent
of nanotechnologies. A participant from a drug development company pointed out that,
among other commercial considerations, clinical proof established in Phase II studies was
required to demonstrate the added value of a new pharmaceutical technology. The participant
from the governmental organization challenged this claim. The participant probed whether
clinical studies were really required in order to convince pharmaceutical companies to invest
in nanotechnologies. This was confirmed by a number of participants and not questioned by
others.
Focus on convincing large pharmaceutical companies by acquiring – hopefully – significant
clinical data (for a specific drug – delivery systems – disease combination) was an important
topic in the workshop. The consideration of evaluation criteria from pharmaceutical compa‐
nies (acting as future selectors of concepts generated by research institutes) by participants
from research institutes and firms implies that these actors did take into account broader
aspects. Still, the discussion was focused on pushing forward nanotechnologies (from the
world of research). The overall strategy itself is predicated on the assumption that convincing
firms and health insurers that clinical evidence is ‘out there’ and that expected benefits only
need to be harvested – after which new drug delivery technologies will enter into the clinics.
This type of reasoning resembles a typical enactor perspective.
One of the participants pointed out further sectoral dynamics. The participant argued that big
pharma had a strong focus on blockbuster drugs and that novel nanotechnology enabled drug
delivery technologies would not likely fall under that class of drugs. This then led to a series
of interactions regarding structural features in the drug delivery sector constraining develop‐
ment of new pharmaceutical technologies in general. During this set of interactions one
participant, who emphasized clinical proof, suggested that if the clinical value would be
convincing, actors (which were left unspecified) could not dismiss these technologies. The
emphasis on benefits, which would overcome all barriers, is a typical enactor perspective. But
this was not left unchallenged. One participant remarked that patients then probably needed
to take action as health insurers might be reluctant to pay for new (costly) therapies. Here, we
see a typical selector argument, pointing out that benefits alone might not be sufficient, as
issues of costs were known to limit introduction of new pharmaceutical therapies.
Participants raised further points to open up the discussion, thereby moving away from the
lock-in on clinical value of drug delivery technologies, which was pushed by a number of
participants. One of the participants challenged the idea of initiating technology development
trajectories from a disease oriented point of view.
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Knowledge institute 3: I would like to react to your comment to take diseases as a starting point. There
are of course many material research groups which start to think from their technology. [...] If you assert
that one needs to start to think from the clinical picture, this means that you actually need to involve
all groups in that discussion. [...] For each disease there are then several delivery systems. Whereas one
could also say that one should start thinking from delivery systems and whether they are toxic or not.
Knowledge institute 2: Yes, but eventually we develop, we produce [...] not things that are safe. No, we
produce things that have to work effectively and which have to help patients [...] Look, it is a bit like,
disease searches for a device, or device searches for a disease.
Microtechnology firm: It is an interaction.
Knowledge institute 2: It is an interaction. And actually I am also in favor of broad academic research.
But, if one takes the step to, let’s call it, valorization, then one needs to make a small value chain and
this should be done by spin-offs.
[..]
Knowledge institute 1: You need them both, of course. You need to have a lot of knowledge about particles
in order to know how and for what you can use them. [..] So, there is a disease and there is a material,
and these should be brought together. How would you like to improve this? Then one would say, for
these connections, these points, there should be programs that support them.
The conclusion that interfaces between actors needed to be improved can be interpreted as a
call for translational research, although the term itself was not employed. The conclusion
shows a non-typical enactor perspective; enactment of new technologies is guided by a
diagnosis of what happens at the level of a sector and what should be improved upon.
4.2.3. Anticipatory strategies: next steps in mobilizing R&D funds and research
The relatively focused discussion created time and space for discussion and articulation of
strategies. Discussions focused on the question of how to further develop nanotechnologies in
the drug delivery sector. Overcoming what was seen as the reverse salient in the overall
development, the lack of clinical evidence, was a central theme in that part of the discussion.
Participants explored possible strategies of co-ordinating developments in the sector, includ‐
ing the creation of a nano drug delivery exemplar which – if successful – might convince the
field of drug delivery of the value of the application of nanotechnologies. Toward the end of
the workshop participants expressed interest and enthusiasm in adopting the discussed
strategy in order to try to actually implement them
Other strategies were explored well. One is particularly interesting as it appealed to the
promise of reducing undesirable side-effects. In the interactions that followed, not only
researchers, enactors, of drug delivery technologies were articulating this strategy, but also
the participant of the governmental organization. One of the participants rebutted this strategy
by referring to negative experiences with large pharmaceutical companies. According to this
participant, the strategy of re-evaluating problematic drugs did not fit with big pharma’s
practices. By providing an account of those experiences, the participant also provided further
insights into the world of large pharmaceutical companies:
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Knowledge institute 1: There is also an opportunity in which one could make up for some costs. There
are of course many pharmaceuticals which in the end have not made it due to side-effects. Targeted
delivery offers an opportunity to avoid such toxic side-effects. The therapeutic effect will probably already
have been demonstrated very clearly, but in the end they have not made it due to the side-effects. In that
respect one may skip some developments, or at least short-cut them and focus on whether one can reduce
these side-effects through targeting.
Knowledge institute 2: Yes, yes, but you can also evoke them [side-effects] via targeting. That automat‐
ically appears, safety, you can not eliminate that, because through linking…
[...]
Knowledge institute 3: Big pharmaceutical companies have many pharmaceuticals on the shelves [which
cannot be used due to drug delivery problems].
Governmental organization: Yes, [...] one should also have a look at the deleted products.
Knowledge institute 2: We have already tried that many times in the past. [...] And eventually it works,
pre-clinically, and they [big pharmaceutical companies] do not do anything with it. Because it doesn’t
fit with their block buster model eventually, and it is too laborious, costs too much money and finally
they pull out. We had spoken already with a number of big pharmaceutical firms in the past about
creating a better life for interesting pharmaceuticals, problem medicine. And, that is, … well, yes, big
pharma does not think that way.
During the discussion of strategies to further the field, also the question of mobilizing resources
for such strategies was put forward for consideration. Toward the end of the meeting the
moderator pointed to one of the scenarios in which patient foundations and organizations
were involved and asked whether that would be a feasible option. Patient organizations can
be involved for financial but also symbolic (moral) support. Participants from research
institutes and the governmental organization were hesitant and argued that it might be too
early to involve them for funding and moral support. Too-high expectations based on too little
evidence and uncertainties over risks were mentioned as reasons (without making explicit the
expected effects). Between the lines, the analyst can see a folk theory of a hype-disappointment
cycle at work.
Interestingly, one of the participants from a firm not directly involved with drug delivery
technologies responded to this discussion by pointing out that little involvement of patient
organizations might induce a pattern reminiscent of the biotech discussions. A pattern, argued
the participant, in which little information by enactors of new technologies is distributed,
leaving civil society organizations to guess what is happening and perhaps leading to a
rejection of new technologies. This was acknowledged by one of the participants from a
research institute as something for which an answer should be developed, but not as something
directly important for the question of furthering the field. This participant considered this
theme as off topic and (again) emphasized the importance of clinical evaluation of new delivery
technologies.
By convening participants at various positions in the chain and facilitating mutual under‐
standing of each other’s positions and perspectives, the workshop supported the participants
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in getting a richer understanding of what happens at the level of the drug delivery sector. This
was acknowledged by one of the participants after the workshop who remarked that the
meeting discussed the big challenges at the level of the domain which was usually not done
as people tend to be preoccupied with their day-to-day affairs.
5. Conclusions
The approach of Constructive Technology Assessment offers a useful methodology and set of
tools such as scenario workshops to support researchers, firms, policy makers and other
stakeholders in identifying dynamics in innovation processes and anticipating plausible future
developments. In this chapter I have described this approach and showed how to actually do
this in the case of nanotechnology-enabled drug delivery systems.
A key finding from the scenario workshop on NDDS is that participants’ assessments of
development dynamics and future market introduction of nanotechnology-enabled drug
delivery systems often took into account what was happening at the level of the sector. That
said, participants did discuss nanotechnology specific aspects, often in the context of uncer‐
tainties about performance, risk and demand for nanotechnology engineered products. Still,
during interactions and positioning of actors, broader considerations about sectoral dynamics
and circumstances came to the fore. Participants discussed patterns of interaction between
actors in the chain and developments at the level of the sector that were independent of, but
relevant for, nanotechnologies. In this way, participants drew from a general repertoire of
embedding issues in their sector, independent of specific emerging technologies, as part of
their anticipatory competences. Discussing dynamics at the level of the sector rather than
Focussing on a specific NDDS technology was appreciated by participants as they usually did
not look at NDDS from such a perspective.
Occasionally participants also discussed issues transcending sectoral aspects such as overall
changes toward dealing with risks of (new) technologies in general and nanotechnology as an
umbrella term. These broader discussions will offer further, though non-specific clues, such
as general pressures to take into account risks of nanotechnologies and take into account ethical
and societal aspects during the development of nanotechnology-enabled products.
Present uncertainties of performance of emerging NDDS will make concrete anticipation of
societal embedding difficult. Then, considerations about sectoral conditions and patterns of
interactions between actors in the sector are likely to be highlighted. This is relevant as a variety
of actors and interests are involved during the development and market introduction of novel
NDDS. Understanding of sector-level patterns linked to drug delivery technologies in general
then offers clues as to what will be important to take into account when working on the
development and introduction of specific combinations of drug delivery devices, pharma‐
ceutical agents and diseases. Scenarios offer playgrounds to experiment with specific cases of
NDDS which will anyway be embedded in dynamics of the intersecting supply chains of
pharmaceuticals and delivery systems.
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By organizing an interactive discussion involving participants at different positions in the
value chain, supported by well-prepared scenarios, analysts or practitioners adopting CTA
methodologies can support articulation of anticipatory strategies and decision making.
Whether the insights gained during such events actually make a difference is more difficult to
determine, among others because this depends on how much opportunities and room to
maneuver participants have after the workshop. The workshops will however contribute to
an emerging shared understanding of dynamics and issues which cannot be easily ignored by
the individual participants. This will be different than before the workshop and in that sense
the workshop will already have effects on how actors will anticipate market introduction of
nanotechnology-enabled drug delivery systems.
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